Knowledge Management System of Hefei Institute of Physical Science,CAS
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements | |
Sun, Yongkun1; Zhang, Wen1; Bi, Xinyu2; Yang, Zhengqiang3; Tang, Yu4; Jiang, Liming5; Bi, Feng6; Chen, Minshan7; Cheng, Shuqun8; Chi, Yihebali1; Han, Yue3; Huang, Jing1; Huang, Zhen2; Ji, Yuan9; Jia, Liqun10; Jiang, Zhichao1; Jin, Jing11; Jin, Zhengyu12; Li, Xiao3; Li, Zhiyu2; Liang, Jun13; Liu, Lianxin14; Liu, Yunpeng15; Lu, Yinying16; Lu, Shichun17; Meng, Qinghua18; Niu, Zuoxing19; Pan, Hongming20; Qin, Shukui21; Qu, Wang1; Shao, Guoliang22; Shen, Feng23; Song, Tianqiang24; Song, Yan1; Tao, Kaishan25; Tian, Aiping26; Wang, Jianhua27; Wang, Wenling28; Wang, Zhe29; Wu, Liqun30; Xia, Feng31; Xing, Baocai32; Xu, Jianming33; Xue, Huadan12; Yan, Dong3; Yang, Lin1; Ying, Jianming34; Yun, Jingping35; Zeng, Zhaochong36; Zhang, Xuewen37; Zhang, Yanqiao38; Zhang, Yefan2; Zhao, Jianjun2; Zhou, Jianguo2; Zhu, Xu39; Zou, Yinghua40; Dong, Jiahong41; Fan, Jia42; Lau, Wan Yee43; Sun, Yan1; Yu, Jinming44; Zhao, Hong2; Zhou, Aiping1; Cai, Jianqiang2 | |
2022-06-01 | |
Source Publication | LIVER CANCER |
ISSN | 2235-1795 |
Corresponding Author | Zhao, Hong(zhaohong@cicams.ac.cn) ; Zhou, Aiping(aiping_zhou@yeah.net) ; Cai, Jianqiang(caijianqiang188@sina.com) |
Abstract | Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. Summary: For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens. Key Messages: Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals. |
Keyword | Chinese interdisciplinary experts Hepatocellular carcinoma Molecular targeted therapy Consensus |
DOI | 10.1159/000521596 |
WOS Keyword | VEIN TUMOR THROMBUS ; TRANSARTERIAL CHEMOEMBOLIZATION ; LIVER-TRANSPLANTATION ; DOUBLE-BLIND ; 1ST-LINE TREATMENT ; PLUS SORAFENIB ; OPEN-LABEL ; PHASE-III ; EFFICACY ; SAFETY |
Indexed By | SCI |
Language | 英语 |
Funding Project | State Key Project on Infection Diseases of China[2017ZX10201021-007-003] ; CAMS Innovation Fund for Medical Sciences (CIFMS)[2017-12M-4-002] ; Non-profit Central Research Institution Fund of Chinese Academy of Medical Sciences[2019PT310026] ; Sanming Project of Medicine in Shenzhen[SZSM202011010] ; Capital Health Research and Development of Special[2018-1-4021] |
Funding Organization | State Key Project on Infection Diseases of China ; CAMS Innovation Fund for Medical Sciences (CIFMS) ; Non-profit Central Research Institution Fund of Chinese Academy of Medical Sciences ; Sanming Project of Medicine in Shenzhen ; Capital Health Research and Development of Special |
WOS Research Area | Oncology ; Gastroenterology & Hepatology |
WOS Subject | Oncology ; Gastroenterology & Hepatology |
WOS ID | WOS:000840263800002 |
Publisher | KARGER |
Citation statistics | |
Document Type | 期刊论文 |
Identifier | http://ir.hfcas.ac.cn:8080/handle/334002/132072 |
Collection | 中国科学院合肥物质科学研究院 |
Corresponding Author | Zhao, Hong; Zhou, Aiping; Cai, Jianqiang |
Affiliation | 1.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 2.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Hepatobiliary Surg, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 3.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Intervent Radiol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 4.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept GCP Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 5.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Diagnost Imaging, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 6.West China Hosp, Dept Med Oncol, Chengdu, Peoples R China 7.Sun Yat Sen Univ Canc Ctr, Dept Hepatobiliary Oncol, Guangzhou, Peoples R China 8.Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China 9.Fudan Univ, Dept Pathol, Zhongshan Hosp, Shanghai, Peoples R China 10.China Japan Friendship Hosp, Dept Oncol Integrat Chinese & Western Med, Beijing, Peoples R China 11.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Radiol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 12.Peking Union Med Coll Hosp, Dept Radiol, Beijing, Peoples R China 13.Peking Univ Int Hosp, Dept Med Oncol, Beijing, Peoples R China 14.Univ Sci & Technol China, Dept Hepat Surg, Affiliated Hosp 1, Hefei, Peoples R China 15.China Med Univ, Dept Med Oncol, Affiliated Hosp 1, Shenyang, Peoples R China 16.Chinese Peoples Liberat Army Gen Hosp, Dept Comprehens Liver Canc Ctr, Med Ctr 5, Beijing, Peoples R China 17.Chinese PLA Med Sch, Chinese Peoples Liberat Army PLA Gen Hosp, Dept Hepatobiliary Surg, Med Ctr 1, Beijing, Peoples R China 18.Capital Med Univ, Beijing Youan Hosp, Dept Clin Care Med Liver Dis, Beijing, Peoples R China 19.Shandong Canc Hosp & Inst, Dept Med Oncol, Jinan, Peoples R China 20.Zhejiang Univ, Sir Run Run Shaw Hosp, Coll Med, Dept Med Oncol, Hangzhou, Peoples R China 21.Nanjing Bayi Hosp, Dept Med Oncol, PLA Canc Ctr, Nanjing, Peoples R China 22.Univ Chinese Acad Sci, Dept Intervent Radiol, Canc Hosp, Hangzhou, Peoples R China 23.Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg Iv, Shanghai, Peoples R China 24.Tianjin Med Univ Canc Inst & Hosp, Dept Hepatobiliary Surg, Tianjin, Peoples R China 25.Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Peoples R China 26.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Tradit Chinese Med, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 27.Fudan Univ, Dept Intervent Radiol, Zhongshan Hosp, Shanghai, Peoples R China 28.Guizhou Med Univ, Guizhou Canc Hosp, Dept Radiol, Affiliated Hosp, Guiyang, Peoples R China 29.Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian, Peoples R China 30.Qingdao Univ, Dept Hepat Biliary Pancreat Surg, Affiliated Hosp, Qingdao, Peoples R China 31.AMU, Dept Hepatobiliary Surg, Southwest Hosp, Chongqing, Peoples R China 32.Beijing Canc Hosp, Dept Hepatobiliary & Pancreat Surg Unit 1, Beijing, Peoples R China 33.Chinese Peoples Liberat Army Gen Hosp, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China 34.Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Pathol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 35.Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Peoples R China 36.Fudan Univ, Dept Radiol, Zhongshan Hosp, Shanghai, Peoples R China 37.Second Hosp Jilin Univ, Dept Hepatobiliary & Pancreat Surg, Changchun, Jilin, Peoples R China 38.Harbin Med Univ Canc Hosp, Dept Oncol, Harbin, Peoples R China 39.Beijing Canc Hosp, Dept Intervent Radiol, Beijing, Peoples R China 40.Peking Univ First Hosp, Dept Intervent Radiol, Beijing, Peoples R China 41.Beijing Tsinghua Changgung Hosp, Dept Hepatopancreatobiliary Surg, Beijing, Peoples R China 42.Fudan Univ, Dept Liver Surg, Zhongshan Hosp, Shanghai, Peoples R China 43.Chinese Univ Hong Kong, Dept Hepat Biliary Pancreat Surg, Hong Kong, Peoples R China 44.Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiol, Tai An, Shandong, Peoples R China |
Recommended Citation GB/T 7714 | Sun, Yongkun,Zhang, Wen,Bi, Xinyu,et al. Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements[J]. LIVER CANCER,2022,11. |
APA | Sun, Yongkun.,Zhang, Wen.,Bi, Xinyu.,Yang, Zhengqiang.,Tang, Yu.,...&Cai, Jianqiang.(2022).Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.LIVER CANCER,11. |
MLA | Sun, Yongkun,et al."Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements".LIVER CANCER 11(2022). |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment